Alkem Laboratories Limited IPO Message Board (Page 31)

Alkem lab or Dr. Lal ka rate kiya chal raha he Rajkot me.

MARKETS ARE NOW CLOSE TO SENSEX 25000 BY 31 DEC 15 AS I HAVE MENTIONED ONE MONTH BACK

hi,
what is max number of lots apply for retail investor in alkem ipo

thx
potugadu

this is a company which is running a complete fraud i have a insider information in which they have trained thier marketing executives to bribe to prescibe thier medicines. for which they offer them gifts and also 3O-5O% cash by cheque which is show as some or the other expense by company usually in connection with the survey or field visit charges.

this is the only company which takes gifts from me to bribe officials.

I think you are not knowing the rules of industry EVERY PHAMA COMPAY USES THE SAME TACTIS
HENCE DO NOT BUY MEDICINE

Alkem Laboratories
Kostak 1700
Gmp 230

Listing above 1300-1350.

Apply with full capacity and you will get unexpected returns.

Capital market ratings

Alkem 48

Dr lal pathlabs 45

Soon to follow IPO of Narayana Hrudayalaya. According to market sources, this IPO may hit the capital market in third week of December. Tentatively by 14th or 15th December. Price band and other details may be announced by next week.

NOW THE QUESTION ARISE HOW MUCH THE RETAIL PORTION WILL SUBSCRIBE. IN ALKEM AND LAL PATH LAB..

IMO both will be over subscribed ALKEM i am applying and Dr LAL i am avoiding

Septa now this is a game all about, the allotment of "how much shares ?" according to grey Alkem may subscribe upto 2 times. Now the more question arises

1. Which option we have to choose, I mean full application or minimum application ( as you told that you are applying for 7 full application.

2. If retail subscribe to LAL with full force then how much subscription in Alkem.

3. There is a very good grey for LAL " is almost 20%", according to my analysis this is a very good GMP and stock rarely list at discount, those have 20% premium. so the lal may get also good subscription from retail. How much it will effect the retail portion of alkem.

4. Now the main and important question, can we calculate the subscription data for retail in advance so that we can put full or minimum application.

According to me if LAL get same response as alkem, Then we may get full allotment in alkem.

Whats your view Now septa. Thanks in advance

please give ipo date nuziwudi seeds

Please gmp of HCG

Anybody please educate about upper circuit on listing day.

Mumbai headquartered, Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales & Its products are also sold in 56 countries. Incorporated in 1973, Alkem Labs is leading  pharmaceutical company engaged in the manufacture and sale of pharmaceutical and neutraceutical products.Alkem Labs has a portfolio of over 736 brands in India. The Company’s most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, vitamins, minerals and nutrients.In the USA , the company has filed 66 ANDA.
Out of its  total 16 manufacturing plants , 14 manufacturing plants are  at five locations in India and two in the USA. It has up four research and development facilities, two in India and two in the USA.The company has MR force of 5745 and has 480 scientists in its  research team.
Interestingly Alkem Lab is ahead of Lupin, GSK pharma in terms of sales
IPO particulars
Issue Size: 12,853,242 equity shares
Face Value: Rs. 2 Per Equity Share
Price Band : Rs.1020 – Rs. 1050 Per Equity Share
Minimum Bid lot : 14 shares and thereafter in multiple of 14 shares.
Listing proposed  at: BSE, NSE
Anchor Issue on  7 Dec 2015
Discount : Rs. 100 to Employees . No discount to Retail investors.
Object of the IPO
To achieve the benefits of listing the Equity Shares on the Stock Exchanges.
Past profitability & valuation analysis :
During the year 2014-15, the company  has earned  total Income of Rs. 33,595.2 crores and  Profit After Tax (PAT)     Rs. 4,37.09.
The company is market leader in various therapeutic areas and has filed large number of ANDA in USA which has solid potential to bring huge spurt in Incomes and profits.During the year 2014-15, it has earned EPS of Rs. 36.70 and has networth of Rs. 251 on consolidated basis. During first 6 months of 2015-16, its has earned basic EPS of Rs.36.10 and net asvalue of rs. 284.
Considering earning potential and already filed ANDA in USA and its leadership position in Indian Pharma market, the share is offered at highly attractive valuation and can fetch very strong returns to investors.

Read RHP in detail. Agree I was wrong on Alkem. Recommended to buy now. Future growth prospects look good on account of robust sales this year at the rate of 33% and profit growing at the rate of 150% for the full year. Plus EPS of 27.5. Buy... Buy...Buy.

Plus friends do not miss out on Dr Lals Pathlabs. Might look expensive but won''t list at discount. Don''t apply enthusiastically but apply for 1/2 lots only. On listing keep a strict stop loss at 540( for retailers 525). And definatly sell at anything beyond 600.

For a person who accompanies a lot of patient, I wondered why Alkem is not listed along with Hindustan Syringes & Medical Devices. Now that it''s coming I will be applying a little after reading through RHP in weekends most likely. But seeing the last 3yrs financial data on Chittorgarh it shows topline growing but not bottomline but past 6 months has given almost last yrs profit. Also, important to collate the data on ANDA filings in US.

Also, Indigo seems to have silenced a lot people it seems now close to 40K crore valuation while Jet or Spice not even 1/5th of it.

Alkem listing expected to be 1400

Can you elaborate your estimate with reasons?

I want to clarify one thing. I am not a broker. I am not a buyer or seller in grey market.

I want to give some brief overview of grey market transaction. Grey market activity runs on trust between broker and investor. You need to go to broker who knows you very well and both have trust on each other. It is almost impossible to sell or buy in other city in grey market. Lots of cash transaction is involved in grey market.

If you sell your application in grey market then you need to give your application details to broker. If you get allotment then broker will sell your application on listing day. Everything in your demat account. You will get selling amount in your bank account directly or by check. Then you need to give total profit after deducting grey market premium cost in cash to broker. Tax liability is yours.

I personally not believe in grey market becaof tax liability.
I am giving an example. If you sell Dr. Lal in grey market for Rs. 1200. Total profit you see Rs. 1200. Suppose you get allotment and Dr. Lal list at Rs. 700 (This is possible becaat present premium is Rs. 90 in grey market). Total profit is 20 (no. of shares) * 150 (listing gain) = 3000 Rs. You need to pay 3000-1200 = Rs. 1800 in cash to broker. However, tax liability is yours. 15% short term gain tax on Rs. 3000 not on Rs. 1200. You need to pay Rs. 450 income tax. Therefore, your total profit is Rs. 1200 – Rs. 450 = Rs. 750.
Why we need to take headache for only Rs. 700 to Rs. 800 ? I am following grey market activity only for future predictions. It is almost 80% probability that if grey market premium on kostak is more than Rs. 1000 then IPO will list at good price and investors will make good money on listing day itself or small period after listing.

If shares not alloted then?

Brokerage is also our liability.
If you are retail investor and apply for 3 minimum application then my experience says you will get one allotment. This is true for worst case scenario also when retail subscription is very high. If you are little lucky then good chances you will get 2 allotment out of 3.
You will still get more money (one allotment) then selling all applications in grey market.

Grey market for both IPOs Alkem and Dr. Lal is very active in Ahmedabad.
Alkem, premium 190, kostak 1450 to 1550
Dr. Lal, premium 90, kostak 1100 to 1175

WHAT IS LATEST KOSTAK PRICE IN Ahmedabad for 1 Lot.